Browsing: Lillys

Mounjaro and Zepbound combined for $12.8 billion of Lilly’s $19.8 billion in first-quarter revenue

Eli Lilly (NYSE: LLY) commands a market capitalization of about $1.06 trillion, and that valuation was built largely on two drugs: Mounjaro and Zepbound. Investors talk about the drugmaker’s weight-loss and diabetes franchise constantly. But it’s worth pinning down what these medicines actually contribute, and the company’s most recent quarterly report gives a concrete answer